Author details

Full Name

Jeremy Hoog

Affiliation

ORCID

Career Start Year

2003

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36609389	A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).		2023
34996889	Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.	Nat Commun	2022
36001024	Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.	Cancer Discov	2022
34429404	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.	Nat Commun	2021
33596420	Cancer-associated exportin-6 upregulation inhibits the transcriptionally repressive and anticancer effects of nuclear profilin-1.	Cell Reports	2021
33371187	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models.	Cancers (Basel)	2020
31665365	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).	J Natl Cancer Inst	2020
30161001	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER<sup>+</sup> breast cancer.	FASEB J	2019
29793947	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.	Clinical Cancer Research	2018
30089255	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.	Cell Rep	2018
29472518	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.	Cancer Res	2018
27869171	Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.	Oncogene	2017
28348404	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.	Nat Commun	2017
28813415	CDK4/6 inhibition triggers anti-tumour immunity.	Nature	2017
28801307	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.	Cancer Discov	2017
28619968	Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity.	Cancer Immunol Res	2017
28612227	Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.	Breast Cancer Research and Treatment	2017
28440318	Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.	Nat Commun	2017
28874413	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer.	Clin Cancer Res	2017
29262642	Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.	Oncotarget	2017
29162134	Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.	Breast Cancer Res	2017
28270497	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.	Clin Cancer Res	2017
27993329	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.	J Mol Diagn	2017
28045625	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).	J Clin Oncol	2017
27502118	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.	Nat Commun	2016
26783290	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical Cancer Research	2016
27486754	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.	Oncotarget	2016
26563128	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clin Cancer Res	2016
24055055	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell Rep	2013
22446188	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.	Journal of Clinical Investigation	2012
22722193	Whole-genome analysis informs breast cancer response to aromatase inhibition.	Nature	2012
21555689	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	J Clin Oncol	2011
20124184	Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.	J Clin Oncol	2010
20393555	Genome remodelling in a basal-like breast cancer metastasis and xenograft.	Nature	2010
19844788	Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.	Breast Cancer Res Treat	2010
19366795	PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.	Cancer Res	2009
18583964	ESR1 gene amplification in breast cancer: a common phenomenon?	Nat Genet	2008
14623913	Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells.	Journal of Experimental Medicine	2003